RxDoctor Payments Data

Neel French, MD

Internal Medicine · Chicago, ILNPI 1417069659

Payments from drug & device makers

$753in general payments, 2019–2025

Across 34 payments — averaging $22.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$208
  • Johnson & Johnson$135
  • Viiv Healthcare Company$114
  • Janssen Products, LP$100
  • Merck$65
  • GSK$59
  • plus $73 from 3 others

What the payments were for

  • Food & beverage$62483%
  • Education$12817%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead9$208
Johnson & Johnson(2 entities)8$135
Viiv Healthcare Company5$114
Janssen Products, LP1$100
Merck4$65
GSK3$59
AbbVie2$45
Pfizer1$16
Theratechnologies Inc.1$12

How this compares

$753 in reported general payments places this provider in the 70th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$12,366
Medicare patients
63
Services billed
113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala84$345,363
DescovyEmtricitabine/Tenofov Alafenam61$153,515
IsentressRaltegravir Potassium40$113,774
TivicayDolutegravir Sodium33$96,109
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf15$83,428
OdefseyEmtricitab/Rilpiviri/Tenof Ala17$71,641
PrezcobixDarunavir/Cobicistat21$68,781
Darunavir24$36,999
OzempicSemaglutide33$29,513
EliquisApixaban20$19,451
Ritonavir16$4,969
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)21$4,426
Atorvastatin Calcium281$3,050
Tenofovir Disoproxil Fumarate11$1,772
ValacyclovirValacyclovir Hcl42$1,268

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$208$498,878145 claims
MerckIsentress$65$113,77440 claims
Viiv Healthcare CompanyTivicay$114$96,10933 claims
Janssen Products, LPSymtuza$100$83,42815 claims
Johnson & JohnsonPrezcobix$135$68,78121 claims
PfizerEliquis$16$19,45120 claims
AbbVieSynthroid$45$88211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →